Bosh sahifaEBS • NYSE
add
Emergent Biosolutions Inc
5,51 $
Seans yopilganidan keyin:(4,17%)+0,23
5,74 $
Yopilgan:13-mar, 19:00:49 (GMT-4) · USD · NYSE · Ogohlantirish
Yopilish kursi
6,15 $
Kunlik diapazon
5,50 $ - 6,23 $
Yillik diapazon
1,82 $ - 15,10 $
Bozor kapitalizatsiyasi
298,55 mln USD
Oʻrtacha hajm
1,28 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NYSE
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 194,70 mln | -29,61% |
Joriy xarajat | 140,80 mln | -33,40% |
Sof foyda | -31,30 mln | 36,77% |
Sof foyda marjasi | -16,08 | 10,17% |
Har bir ulushga tushum | 0,05 | 106,49% |
EBITDA | 21,00 mln | 255,56% |
Amaldagi soliq stavkasi | -13,41% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 99,50 mln | -10,92% |
Jami aktivlari | 1,39 mlrd | -23,78% |
Jami passivlari | 906,90 mln | -22,74% |
Umumiy kapital | 482,80 mln | — |
Tarqatilgan aksiyalar | 54,34 mln | — |
Narxi/balansdagi bahosi | 0,69 | — |
Aktivlardan daromad | -0,75% | — |
Kapitaldan daromad | -0,92% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -31,30 mln | 36,77% |
Operatsiyalardan naqd pul | -79,90 mln | -348,91% |
Sarmoyadan naqd pul | 28,60 mln | 350,88% |
Moliyadan naqd pul | 500,00 ming | -89,36% |
Naqd pulning sof oʻzgarishi | -50,80 mln | -312,55% |
Boʻsh pul | -5,54 mln | -113,72% |
Haqida
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid.
During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
Tashkil etilgan
5-sen, 1998
Xodimlar soni
900
